DDInter1590 DDInter899
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifampicin {u} (Compound) treats {v} (Disease) leprosy
Rifampicin {u} (Compound) binds {v} (Gene) ABCC2
Rifampicin {u} (Compound) is included by {v} (Pharmacologic Class) Rifamycins
Rifampicin {u} (Compound) downregulates {v} (Gene) TIMP1
Rifampicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxepin
Rifampicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aluminum hydroxide
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Rifampicin (Compound) resembles Rifabutin (Compound)
Rifampicin (Compound) treats leprosy (Disease)
Rifampicin (Compound) binds ABCC2 (Gene)
Rifampicin (Compound) is included by Rifamycins (Pharmacologic Class)
Rifampicin (Compound) downregulates TIMP1 (Gene)
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Doxepin
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Rifampicin may lead to a major life threatening interaction when taken with Elagolix